Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. (July 2016)

• Record Type: Journal Article
• Authors: Held, Peter; Himmelmann, Anders; Ditmarsch, Marc
• Is Part Of: Future cardiology. Volume 12:Number 4(2016)
• Page Start: 405
• Page End: 418
• Publication Date: 2016-07
• Subjects: acute coronary syndrome -- atherosclerosis -- coronary artery disease -- diabetes mellitus -- myocardial infarction -- P2Y12 receptor antagonist -- ischemic stroke -- ticagrelor; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca-2016-0028
• Languages: English
• ISSNs: 1479-6678

Abstract

Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials.gov: NCT00391872) and in patients with a history of myocardial infarction (PEGASUS-TIMI 54; ClinicalTrials.gov: NCT01225562). Ongoing trials will provide information on the efficacy and safety of ticagrelor in patients with acute ischemic stroke or transient ischemic attack (SOCRATES; ClinicalTrials.gov: NCT01994720), peripheral artery disease (EUCLID; ClinicalTrials.gov: NCT01732822) and coronary artery disease in patients with Type 2 diabetes mellitus (THEMIS: ClinicalTrials.gov: NCT01991795).